

## **Clinical Policy: Migraine Acute Treatment Agents**

Reference Number: PHW.PDL.021

Effective Date: 01/05/2021

Last Review Date: 11/2024

### **Policy/Criteria**

*Provider must submit documentation (such as office chart notes, lab results or other clinical information) supporting that member has met all approval criteria.*

It is the policy of PA Health and Wellness® that Migraine Acute Treatment Agents are **medically necessary** when the following criteria are met:

### **I. Requirements for Prior Authorization of Migraine Acute Treatment Agents**

#### **A. Prescriptions That Require Prior Authorization**

Prescriptions for Migraine Acute Treatment Agents that meet any of the following conditions must be prior authorized:

1. A non-preferred Migraine Acute Treatment Agent. See the Preferred Drug List (PDL) for the list of preferred Migraine Acute Treatment Agents at: <https://papdl.com/preferred-drug-list>.
2. A Migraine Acute Treatment Agent with a prescribed quantity that exceeds the quantity limit.
3. A Migraine Acute Treatment Agent when there is a record of a recent paid claim for another Migraine Acute Treatment Agent (therapeutic duplication).
4. A prescription for a small molecule calcitonin gene-related peptide (CGRP) receptor antagonist (gepant).
5. A prescription for a serotonin (5-HT) 1F receptor agonist (ditan).
6. A prescription for an ergot alkaloid.

#### **B. Review of Documentation for Medical Necessity**

In evaluating a request for prior authorization of a prescription for a Migraine Acute Treatment Agent, the determination of whether the requested prescription is medically necessary will take into account the whether the member:

1. For a gepant for the preventive treatment of migraine, see **PHW.PDL.537 Migraine Prevention Agents**; **OR**
2. **Both** of the following:

- a. Is being treated for a diagnosis that is indicated in the U.S. Food and Drug Administration (FDA)-approved package labeling OR a medically accepted indication
- b. Has a diagnosis confirmed according to the current International Headache Society Classification of Headache Disorders;

**AND**

3. Is age-appropriate according to FDA-approved package labeling, nationally recognized compendia, or peer-reviewed medical literature; **AND**
4. Is prescribed a dose that is consistent with FDA-approved package labeling, nationally recognized compendia, or peer-reviewed medical literature; **AND**
5. Does not have a contraindication to the prescribed medication; **AND**
6. For a gepant for the acute treatment of migraine:
  - a. **One** of the following:
    - i. Has a history of therapeutic failure of at least two (5-HT<sub>1B/1D</sub>) receptor agonists (triptans)
    - ii. Has a contraindication or intolerance to the preferred triptans,

**AND**

7. For a ditan, has a history of trial and failure, contraindication, or intolerance to the preferred triptans; **AND**
8. For ergot alkaloids, has a history of trial and failure, contraindication, or intolerance to standard first-line abortive medications based on headache classification as recommended by current consensus guidelines (such as guidelines from the American Academy of Neurology, American Academy of Family Physicians, American Headache Society); **AND**
9. For a non-preferred Migraine Acute Treatment Agent, **one** of the following:
  - a. For a non-preferred triptan, has a history of therapeutic failure, contraindication, or intolerance to the preferred triptans,
  - b. For a non-preferred gepant, has a history of therapeutic failure of or a contraindication or an intolerance to the preferred gepants,
  - c. For all other non-preferred Migraine Acute Treatment Agents other than triptans and gepants (e.g., ditans, ergot alkaloids, etc.), has a history of therapeutic failure, contraindication, or intolerance to the preferred Migraine Acute Treatment Agents approved or medically accepted for the member's diagnosis or indication;

**AND**

10. For therapeutic duplication, **one** of the following:

- a. Is being titrated to or tapered from another medication in the same class
- b. Has a medical reason for concomitant use of the requested medications that is supported by peer-reviewed medical literature or national treatment guidelines;

**AND**

11. If a prescription for a Migraine Acute Treatment Agent is for a quantity that exceeds the quantity limit, the determination of whether the prescription is medically necessary will also take into account **all** of the following:

- a. The guidelines set forth in PA.CP.PMN.59 Quantity Limit Override,
- b. Whether the member is prescribed the requested medication by **one** of the following:
  - i. A neurologist
  - ii. A headache specialist who is certified in headache medicine by the UCNS,
- c. For the acute treatment of migraine, **both** of the following:
  - i. **One** of the following:
    - a) The member is using the requested medication in addition to at least one medication for migraine prevention (e.g., beta-blocker, anticonvulsant, antidepressant, CGRP monoclonal antibody, gepant, botulinum toxin)
    - b) The member has a history of therapeutic failure, contraindication, or intolerance to all preventive migraine medications recommended by current consensus guidelines (such as guidelines from the American Academy of Neurology, American Academy of Family Physicians, American Headache Society)
  - ii. Has documentation of an evaluation for the overuse of abortive medications, including opioids.

NOTE: If the member does not meet the clinical review guidelines listed above but, in the professional judgment of the physician reviewer, the services are medically necessary to meet the medical needs of the member, the request for prior authorization will be approved.

**FOR RENEWALS OF PRIOR AUTHORIZATION FOR A MIGRAINE ACUTE TREATMENT AGENT:** The determination of medical necessity of a request for renewal

of a prior authorization for a Migraine Acute Treatment Agent that was previously approved will take into account whether the member:

1. Is prescribed a dose that is consistent with FDA-approved package labeling, nationally recognized compendia, or peer-reviewed medical literature; **AND**
2. Does not have a contraindication to the prescribed medication; **AND**
3. Has documentation of improvement in headache pain, symptoms, or duration; **AND**
4. For a non-preferred Migraine Acute Treatment Agent, one of the following:
  - a. For a non-preferred triptan, has a history of therapeutic failure of or a contraindication or an intolerance to the preferred triptans,
  - b. For a non-preferred gepant, has a history of therapeutic failure of or a contraindication or an intolerance to the preferred gepants,
  - c. For non-preferred Migraine Acute Treatment Agents other than triptans and gepants (e.g., ditans, ergot alkaloids, etc.), has a history of therapeutic failure of or a contraindication or an intolerance to the preferred Migraine Acute Treatment Agents approved or medically accepted for the beneficiary's diagnosis or indication;

**AND**

5. For therapeutic duplication, one of the following:
  - a. Is being titrated to or tapered from another medication in the same class
  - b. Has a medical reason for concomitant use of the requested medications that is supported by peer-reviewed medical literature or national treatment guidelines;

**AND**

6. If a prescription for a Migraine Acute Treatment Agent is for a quantity that exceeds the quantity limit, the determination of whether the prescription is medically necessary will also take into account **all** of the following:
  - a. The guidelines set forth in PA.CP.PMN.59 Quantity Limit Override,
  - b. Whether the member is prescribed the requested medication by **one** of the following:
    - i. A neurologist
    - ii. A headache specialist who is certified in headache medicine by the UCNS,
  - c. For the acute treatment of migraine, **both** of the following:
    - i. **One** of the following:
      - a) The member is using the requested medication in addition to at least one medication for migraine prevention (e.g., beta-blocker, anticonvulsant, antidepressant, CGRP monoclonal antibody, gepant, botulinum toxin)

- b) The member has a history of therapeutic failure, contraindication, or intolerance to all preventive migraine medications recommended by current consensus guidelines (such as guidelines from the American Academy of Neurology, American Academy of Family Physicians, American Headache Society)
- ii. Has documentation of an evaluation for the overuse of abortive medications, including opioids.

NOTE: If the member does not meet the clinical review guidelines listed above but, in the professional judgment of the physician reviewer, the services are medically necessary to meet the medical needs of the member, the request for prior authorization will be approved.

**B. Clinical Review Process**

Prior authorization personnel will review the request for prior authorization and apply the clinical guidelines in Section B. above to assess the medical necessity of a prescription for a Migraine Acute Treatment Agent. If the guidelines in Section B. are met, the reviewer will prior authorize the prescription. If the guidelines are not met the prior authorization request will be referred to a physician reviewer for a medical necessity determination. Such a request for prior authorization will be approved when, in the professional judgment of the physician reviewer, the services are medically necessary to meet the medical needs of the member.

**C. References**

1. (2021), 63rd Annual Scientific Meeting American Headache Society®. Headache: The Journal of Head and Face Pain, 61: 1-178. <https://doi.org/10.1111/head.14130>
2. Almotriptan Package Insert. North Wales, PA: Teva Pharmaceuticals USA, Inc.; May 2017.
3. American Headache Society. The American Headache Society position statement on integrating the new migraine treatments into clinical practice. Headache. 2019;59:1-18.
4. D.H.E. 45 Package Insert. Bridgewater, NJ: Bausch Health US, LLC; April 2022.
5. Frova Package Insert. Malvern, PA: Endo Pharmaceuticals Inc.; August 2018.
6. Imitrex Package Insert. Durham, NC: GlaxoSmith Kline; February 2024.
7. Institute for Clinical Systems Improvement. Diagnosis and treatment of headache. eleventh edition. January 2013.
8. International Headache Society. Headache Classification Committee of the International Headache Society (IHS): the international classification of headache disorders, 3rd edition. Cephalalgia. 2018; Vol. 38(1):1-211.
9. Mack KJ. Acute treatment of migraine in children. Patterson MC, Swanson JW, Goddeau Jr. RP, eds. Waltham, MA: UpToDate Inc. Updated May 08, 2023. Accessed August 19, 2024.
10. Maxalt Package Insert. Jersey City, NJ: Organon LLC; June 2021.

11. Mayans L, Walling A. Acute migraine headache: treatment strategies. American Family Physician. 2018;97(4):243-251.
12. Migranal Package Insert. Bridgewater, NJ: Bausch Health US, LLC; September 2022.
13. Naratriptan Package Insert. Princeton, NJ: Bionpharma Inc.; December 2023.
14. Nurtec ODT Package Insert. New York, NY: Pfizer Labs; April 2023.
15. Relpax Package Insert. New York, NY: Roerig Division of Pfizer Inc.; March 2020.
16. Reyvow Package Insert. Indianapolis, IN: Eli Lilly and Company; September 2022.
17. Schwedt TJ, Garza I. Acute treatment of migraine in adults. Swanson JW, Goddeau Jr. RP, eds. Waltham, MA: UpToDate Inc. Updated July 22, 2024. Accessed August 19, 2024.
18. Tosymra Package Insert. Princeton, NJ: Promius Pharma, LLC; January 2019.
19. Treximet Package Insert. Brentwood, TN: Currax Pharmaceuticals LLC; February 2024.
20. Trudhesa Package Insert. Milano, Italy: Mipharm, S.p.A.; August 2023.
21. Ubrelvy Package Insert. North Chicago, IL: AbbVie Inc. June 2023.
22. Zembrace SymTouch Package Insert. Princeton, NJ: Promius Pharma; June 2019.
23. Zomig Package Insert. Bridgewater, NJ: Amneal Specialty; March 2022.

Reviews, Revisions, and Approvals	Date
Q1 2021: policy created according to DHS effective 01/05/2021	11/2020
Q1 2022: revised according to DHS revisions effective 01/03/2022	10/2021
Q1 2023 annual review: no changes.	11/2022
Q1 2024 annual review: no changes.	11/2023
Q1 2025: policy revised according to DHS revisions effective 01/06/2025.	11/2024